Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
Clinical trial NCT02286219 · COMPLETED
Trial details
- NCT number
- NCT02286219
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-04
- Primary completion
- 2017-06-08
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.